Abstract
The purpose of this study was to evaluate urinary nuclear matrix protein 22 (NMP22) as a marker for urinary bladder cancer. Four groups of subjects participated in this study : 18 with a history of bladder cancer without tumors, 12 with urinary bladder tumors, 9 with prostate cancer, and 2 with renal cell cancer. All patients provided a urine sample for urinary NMP22. All bladder cancer patients provided urine cytology before the cystoscopic examination. The mean urinary NMP22 value was 4.6U/ml in bladder cancer patients without tumors, 190.8U/ml in bladder cancer patients with tumors, and 5.8U/ml in patients with other diseases. The NMP22 value in bladder cancer patients with tumors was significantly higher than that in the other groups. The sensitivity and specificity of urinary NMP22 in urinary bladder cancer was 75% and 100%, respectively, and the sensitivity of NMP22 was higher than that of urine cytology. This study indicates that urinary NMP22 is a sensitive, non-invasive marker for detecting urinary bladder cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
